Condition (MeSH)
Rhinitis
ClinicalTrials.gov lists 1,345 trials for Rhinitis or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 79.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
212 of the 1,345 trials are tagged with Rhinitis itself; the rest are tagged with a narrower condition beneath it.
When did Rhinitis trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 83
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 34 |
| 2025 | 62 |
| 2024 | 54 |
| 2023 | 50 |
| 2022 | 52 |
| 2021 | 46 |
| 2020 | 39 |
| 2019 | 41 |
| 2018 | 43 |
| 2017 | 29 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 47 trials starting in 2026 and about 56 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 18 months from start to primary completion across 50 trials still running at the 2026-10-09 snapshot; registered median of 8 months across 1,011 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Rhinitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 107 |
| Phase 1/2 | 34 |
| Phase 2 | 198 |
| Phase 2/3 | 22 |
| Phase 3 | 294 |
| Phase 4 | 197 |
| Not applicable | 269 |
| Observational | 224 |
How many Rhinitis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 39 |
| Recruiting | 59 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 19 |
| Completed | 1,004 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Rhinitis trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 79 |
| Organon and Co | 72 |
| ALK-Abelló A/S | 30 |
| AstraZeneca | 24 |
| UCB Pharma | 17 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Rhinitis? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| OPN-375 | 39 |
| Montelukast | 29 |
| LYR-210 | 22 |
| Loratadine | 20 |
| Bilastine | 12 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Levocetirizine only | 32 |
| Cetirizine drops | 31 |
| Desloratadin | 30 |
| Fluticasone foroate | 21 |
| Mometasone furoate as a nasal spray | 20 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Rhinitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 22 | 17 |
| Asthma | 18 | 8 |
| Abortion spontaneous | 11 | 8 |
| Pneumonia | 11 | 9 |
| Pregnancy | 10 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Rhinitis? (792)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. | Allergy | 2025 | Yes |
| The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps. | Ear, nose, & throat journal | 2025 | Yes |
| Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 2025 | Yes |
| Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. | International forum of allergy & rhinology | 2025 | Yes |
| Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. | Scientific reports | 2025 | Yes |
Showing 5 of 792 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.